Media

Media

Recent News

  • Avivagen Announces Largest Order To-Date for OxC-beta™ Livestock

    Ottawa, ON / TNW-Accesswire / June 25, 2018 / – Avivagen Inc. (TSXV:VIV) (“Avivagen” or the “Corporation”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that, by safely supporting immune function, promote general health and performance, is pleased to announce that its partner in the Philippines, …Read More

  • Avivagen to Exhibit Vivamune at SuperZoo

    Ottawa, ON / TNW-Accesswire / June 22, 2018 / – – Avivagen Inc. (TSXV:VIV)(“Avivagen” or the “Corporation”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that, by safely supporting immune function, promote general health and performance, is pleased to announce that it will be exhibiting Vivamune …Read More

  • Avivagen Announces Distribution Agreement in Thailand

    Ottawa, ON / TNW-Accesswire / June 13, 2018 / – Avivagen Inc. (TSXV:VIV)(“Avivagen” or the “Corporation”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that, by safely supporting immune function, promote general health and performance, is pleased to announce that it has signed a distribution agreement …Read More

  • Avivagen Announces Q2 Financial Results

    Ottawa, ON / TNW-Accesswire / June 5, 2018 / – – Avivagen Inc. (TSXV:VIV)(“Avivagen” or the “Corporation”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that, by safely supporting immune function, promote general health and performance, today reported its financial results for Q2, 2018.  Unless otherwise …Read More

  • Avivagen Announces Distribution in China for Vivamune

    Ottawa, ON / TNW-Accesswire / June 1, 2018 / – Avivagen Inc. (TSXV:VIV)(“Avivagen” or the “Corporation”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that, by safely supporting immune function, promote general health and performance, is pleased to announce that it has made its first sale …Read More

View All News Releases

Media Coverage

  • VICTAM Asia

    Avivagen CEO Interviewed at VICTAM Asia 2018 Conference

    Avivagen recently debuted at the VICTAM ASIA 2018 Conference in Bangkok, Thailand.

  • CEO Kym Anthony Interviewed by Uptick

    CEO Kym Anthony was interviewed by the penny stock news and trends podcast, Uptick Newswire.

    I think if people keep their eyes on the size of the prize, [they’ll see] the livestock market is in the billions of dollars; our share of that would be in the hundreds of millions if we roll out successfully. The human market is untouched. The companion animal market is also big. We’ve spent years proving it works; everyone agrees it works. Now is the time to roll it out commercially.

  • CTV: Growing resistance to antibiotics fuels market for alternative solutions

    CTV NEWS, TORONTO – A hundred years ago, a small wound could result in death if an infection spread. That could become reality again as the world threatens to return to a pre-antibiotic era due to antibiotic resistance.

    Some have pointed to the widespread use of antibiotics in livestock feed as a culprit, resulting in urgent calls to quell their use and find alternatives.

View All Media Coverage